|
注册号: Registration number: |
ChiCTR1900024587 |
|
最近更新日期: Date of Last Refreshed on: |
2019-07-18 16:23:46 |
|
注册时间: Date of Registration: |
2019-07-18 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
该研究尚未获得伦理委员会批准。请于批准后才开始纳入参试者,并与我们联系上传批件。 不同浓度罗哌卡因联合舒芬太尼对不同体重指数产妇分娩镇痛的应用效果:前瞻、随机、双盲、对照研究 |
|
Public title: |
Effect of different concentrations of ropivacaine combined with sufentanil on labor analgesia in patients with different body mass index |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
不同浓度罗哌卡因联合舒芬太尼对不同体重指数产妇分娩镇痛的应用效果:前瞻、随机、双盲、对照研究 |
|
Scientific title: |
Effect of different concentrations of ropivacaine combined with sufentanil on labor analgesia in patients with different body mass index |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
陶磊 |
研究负责人: |
疏树华 |
|
Applicant: |
Tao Lei |
Study leader: |
Shu Shuhua |
|
申请注册联系人电话: Applicant telephone: |
+86 18656004030 |
研究负责人电话:
Study leader's |
+86 15375472196 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
taoisheihei@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
sshhf@189.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
安徽省合肥市庐阳区庐江路17号 |
研究负责人通讯地址: |
安徽省合肥市庐阳区庐江路17号 |
|
Applicant address: |
17 Lujiang Road, Luyang District, Hefei, China |
Study leader's address: |
17 Lujiang Road, Luyang District, Hefei, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
中国科学技术大学附属第一医院 |
||
|
Applicant's institution: |
The First Affiliated Hospital of USTC (Anhui Provincial Hospital) |
||
|
研究负责人所在单位: |
中国科学技术大学附属第一医院 |
||
|
Affiliation of the Leader: |
The First Affiliated Hospital of USTC (Anhui Provincial Hospital) |
||
|
是否获伦理委员会批准: |
否 |
||
|
Approved by ethic committee: |
No |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
伦理委员会批件附件: Approved file of Ethical Committee: |
||
|
批准本研究的伦理委员会名称: |
|
||
|
Name of the ethic committee: |
|
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2013-08-26 00:00:00 | ||
|
伦理委员会联系人: |
|
||
|
Contact Name of the ethic committee: |
|
||
|
伦理委员会联系地址: |
|
||
|
Contact Address of the ethic committee: |
|
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
中国科学技术大学附属第一医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The First Affiliated Hospital of USTC (Anhui Provincial Hospital) |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
安徽省合肥市庐阳区庐江路17号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
17 Lujiang Road, Luyang District, Hefei, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
中国科学技术大学附属第一医院麻醉科 |
||||||||||||||||||||||
|
Source(s) of funding: |
Department of anesthesiology,the First Affiliated hospital of ustc |
||||||||||||||||||||||
|
研究疾病: |
分娩镇痛 |
||||||||||||||||||||||
|
Target disease: |
labor analgesia |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
不同剂量对照 |
||||||||||||||||||||||
|
Study design: |
Dose comparison |
||||||||||||||||||||||
|
研究目的: |
通过比较不同浓度罗哌卡因联合舒芬太尼用于不同体重指数行分娩镇痛产妇的应用效果,探究不同罗哌卡因浓度及体重指数是否会影响分娩镇痛效果。 |
||||||||||||||||||||||
|
Objectives of Study: |
The objective of the study is to evaluate the influence of body mass index(BMI)(normal,overweight,obese) and the concentration of ropivacaine on the performance of epidural analgesia in labor analgesia. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1) 产妇拒绝; |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Patient refusal to participate in the study; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2019-07-20 00:00:00至 To 2020-07-20 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2019-07-20 00:00:00 至 To 2020-07-20 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
Microsoft excel2007随机数字表 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Random number table generated by excel 2007 |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
未说明 |
|
Blinding: |
Not stated |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
临床试验公共管理平台ResMan |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
ResMan research manager |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
临床试验公共管理平台ResMan |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
ResMan research manager |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |